
Curis (CRIS) Stock Forecast & Price Target
Curis (CRIS) Analyst Ratings
Bulls say
Curis is a biotechnology company that specializes in the development and commercialization of drugs and therapies for solid tumors and a variety of cancers. The company's pipeline products, including Fimepinostat, CA-170, and Erivedge, show promise in treating various types of cancers, with encouraging data and high response rates in recent trials. With a robust portfolio and a strategic focus on expanding its drugs across different cancer subtypes, Curis is well positioned for growth and success in the future.
Bears say
Curis is facing challenges with its pipeline products in the immuno-oncology and precision oncology therapeutic areas due to slower-than-expected enrollment in its registrational trial for PCNSL, potentially delaying full approval and revenue generation. Additionally, the company may struggle with funding a randomized, three-arm study in a rare CNS lymphoma population ahead of its submission, further compounding its financial pressures. Given these challenges and potential delays, Curis's stock outlook remains negative.
This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.
Curis (CRIS) Analyst Forecast & Price Prediction
Start investing in Curis (CRIS)
Order type
Buy in
Order amount
Est. shares
0 shares